Institute Curie Hospital, First in France to Install TomoTherapy(R) Hi-Art(R) treatment system



    TomoTherapy Incorporated announced today that France's Institute
    Curie Hospital has acquired the first TomoTherapy Hi-Art system to be
    used in France. The Institute Curie Hospital announced the acquisition
    with a tour of the treatment area and a reception hosted by Professor
    Claude Huriet, President of the Institute Curie, on March 7th, 2007.
    Notable attendees included Professor Dominque Maranchi, President of
    the National Institute of Cancer (INCA) and Marc Lipinski,
    Vice-President of the Regional Council, IIe-de-France.

    A private foundation comprised of France's largest cancer research
    center and a leading public hospital, the Institute Curie was founded
    in 1909 by Marie Curie. Since receiving state approval in 1921, the
    Institute Curie has made developing innovative and individualized
    treatments, and ensuring availability of the most advanced techniques,
    among its chief priorities.

    "We are pleased to have the TomoTherapy Hi-Art system being used
    by a pioneering institution so notably linked to the field of
    radiation," said TomoTherapy Inc. CEO, Dr. Fred Robertson.

    The decision by the Institute Curie Hospital to install the
    TomoTherapy Hi-Art system follows calls for research proposals
    launched by the National Cancer Institute in July 2005 to promote
    implementation of image-guided radiation therapy technology that was
    not previously available in France. Two other centers in France,
    Nantes and Bordeaux, intend to install the TomoTherapy Hi-Art system
    as a result of the proposals' recommendations.

    About TomoTherapy Incorporated

    TomoTherapy Incorporated has developed, manufactures and sells the
    Hi-Art(R) system, one of the most advanced and versatile radiation
    therapy systems commercially available for the treatment of a wide
    variety of cancers. TomoTherapy Incorporated markets the Hi-Art(R)
    system to hospitals and cancer treatment centers in North America,
    Europe and Asia.